Questcor Pharmaceuticals Reports Strong Finish to 2010

Questcor Pharmaceuticals, Inc. QCOR today reported a strong finish to 2010. The Company estimates that 353 new, paid Acthar prescriptions for the treatment of multiple sclerosis were filled and shipped during the quarter, up 66% from the year ago period and up 9% from the third quarter of 2010. 1,680 vials and 6,666 vials of the company's principal drug, H.P. Acthar Gel, were shipped during the quarter and year ended December 31, 2010. As expected, operating expenses for the fourth quarter are estimated to be several million dollars higher than the third quarter of 2010, reflecting the company's increased investment in sales and marketing activities for Acthar.